In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TorreyPines Therapeutics Inc.

Division of Horizon Therapeutics PLC
www.torreypinestherapeutics.com

Latest From TorreyPines Therapeutics Inc.

Mirati names chief medical and development officer

San Diego, California-based Mirati Therapeutics has named Isan Chen chief medical and development officer. Dr Chen joins Mirati – a targeted oncology company – from Aragon Pharmaceuticals, where he was chief medical officer. Aragon was acquired by big pharma Johnson & Johnson earlier this year. Meanwhile, Mirati has also appointed Craig Johnson to its board of directors and as chair of the audit committee. Mr Johnson was previously chair of the audit committee on the boards of Ardea Biosciences and Adamis Pharmaceuticals. He was also CFO of TorreyPines Therapeutics and NovaDel Pharma.

Abbott makes strategic investment in small neuro biotech

Abbott Biotech Ventures has made a strategic investment of undisclosed value in privately held company, NeuroGenetic Pharmaceuticals, to expedite the development of a small molecule candidate for the prevention of Alzheimer's disease. Although the Abbott investment is likely to be less than $3 million, NeuroGenetic’s management believes that it provides industry validation for its approach.

Neurology

NovaDel Pharma makes appointment

NovaDel Pharma (US) has appointed Craig Johnson senior vice-president, chief financial officer and secretary. The company's chairman, president and chief executive officer, Steven Ratoff, had been serving interim CFO and secretary since April 2009. Mr Johnson served as vice-president and CFO of TorreyPines Therapeutics from 2004 until its sale to Raptor Pharmaceutical in September 2009. Following the sale, he was vice-president of TPTX, a subsidiary of Raptor, until April this year. NovaDel is a speciality pharmaceutical company developing oral spray formulations for a range of marketed drugs.

Companies

Mind over matter - partnerships: CNS deals signed over the past five years

Attention deficit hyperactivity disorder (ADHD)

Date

 

Company

 

Partner

 

Deal terms

 

March 2009

 

GlaxoSmithKline

 

Shire

 

co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US

 

November 2008

 

GlaxoSmithKline

 

Paladin Labs

 

three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada

 

Neurology Mexico
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Axonyx Inc.
  • Neurogenetics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Horizon Therapeutics PLC
  • Senior Management
  • Contact Info
  • TorreyPines Therapeutics Inc.
    Phone: (858) 623-5665
    11085 N. Torrey Pines Rd.
    Ste. 300
    La Jolla, CA 92037
    USA
UsernamePublicRestriction

Register